News Article | February 28, 2017
According to a new market research report "Cognitive Assessment and Training in Healthcare Market by Assessment Type (Pen-and-Paper Based, Hosted, and Biometrics), Components, Application (Clinical Trial, Screening & Diagnostics, Brain Training, Academic Research), & Region - Global forecast to 2021", published by MarketsandMarkets, the market size estimated to grow from USD 962.0 Million in 2016 to USD 4,127.2 Million by 2021, at a Compound Annual Growth Rate (CAGR) of 33.8%. Browse 56 market data Tables and 44 Figures spread through 138 Pages and in-depth TOC on "Cognitive Assessment and Training in Healthcare Market" http://www.marketsandmarkets.com/Market-Reports/cognitive-assessment-training-healthcare-market-191532711.html Early buyers will receive 10% customization on this report. The major forces driving this market are aging global population, increasing awareness about brain fitness, and advancements in technology. The growing market for cognitive solutions and increasing demand for brain training by next-generation tech-savvy population are contributing to the growth of the Cognitive Assessment and Training in Healthcare Market. Clinical trials in terms of application is expected hold the largest market share in the Cognitive Assessment and Training in Healthcare Market during the forecast period Clinical trials are mainly used to identify, measure, or monitor cognitive impairments and cognitive changes. The assessment of cognitive functions is an integral part of decision making during clinical drug development, as certain drugs can have an impact on the cognitive capabilities of the brain. The market is expected to contribute the highest revenue for vendors offering clinical trials. Service segment is expected to grow at the highest CAGR in the Cognitive Assessment and Training in Healthcare Market and the current trend is expected to continue during the forecast period An Increasing demand for cognitive assessment and training tests and procedures in the global healthcare market also provides a significant scope for associated services as well. The growth of the services segment is expected to accelerate, due to an increasing level of awareness regarding the brain fitness. With the increasing utilization of cognitive assessment and training solutions, the services act as an add-on to these solutions making them more valuable. Providers of cognitive assessment and training solutions and services offer training and coaching services to deliver balanced cognitive rehabilitation solutions. North America is expected to contribute the largest market share and Asia-Pacific (APAC) to grow at the highest rate North America is expected to hold the largest market share and to dominate the Cognitive Assessment and Training in Healthcare Market from 2016 to 2021, due to the increasing awareness among population about adopting medication for cognitive diseases. The new generation in this region is more concerned towards the benefits of cognitive training, which is not just limited to patients with cognitive dysfunctions. The U.S. market holds a majority of the market share in terms of adoption as well as revenue generation in the North American market, due to the rapidly aging population vulnerable to cognitive diseases in the region. The APAC region is expected to witness the highest growth rate during the forecast period, as the population in the region is more inclined towards adopting a healthier lifestyle. Hence, the concerns regarding cognitive diseases are growing in the region. The major vendors in the Cognitive Assessment and Training in Healthcare Market include Cambridge Cognition Ltd. (Cambridge, U.K.), Cogstate Ltd. (New Haven, U.S.), Bracket (Pennsylvania, U.S.), MedAvante Inc. (New Jersey, U.S.), Quest Diagnostic (New Jersey, U.S.), ProPhase, LLC (New York, U.S.), CogniFit (New York, U.S.), ERT Clinical (Pennsylvania, U.S.), NeuroCog Trials (North Carolina, U.S.), and Brain Resource Company (New South Wales, Australia). Cognitive Computing Market by Technology (Natural Language Processing, Machine Learning, Automated Reasoning), by Deployment Model (On-Premises, Cloud) & by Regions - Global Forecast to 2019 http://www.marketsandmarkets.com/Market-Reports/cognitive-computing-market-%20136144837.html Cognitive Assessment and Training Market by Assessment Type (Pen & Paper Based, Hosted, Biometrics), Service, Application (Clinical Trials, Classroom Learning, Brain Training, Corporate Learning, Academic Research), Vertical and Region - Global Forecast to 2020 http://www.marketsandmarkets.com/Market-Reports/cognitive-assessment-market-1039.html Know More About our Knowledge Store @ http://www.marketsandmarkets.com/Knowledgestore.asp MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers. We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. Visit MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com/market-reports/telecom-it Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: HEALTH-2009-1.4-1 | Award Amount: 16.14M | Year: 2010
There are currently no cures for Parkinsons disease (PD) but one of the most effective reparative therapies in patients to date has been with allotransplants of dopamine (DA) neuroblasts obtained from fetal ventral mesencephalic (VM) tissue. However, this cell transplantation approach has given inconsistent results, with some patients doing extremely well and coming off anti-PD medication for years, whilst others have shown no or only modest clinical improvements, and in some cases also developed severe, off-state graft-induced dyskinesias (GIDs). The reasons behind this heterogeneity of outcomes, and the emergence of GIDs in particular, need to be better understood, not least in the perspective of the rapid advances that are now being made in the development of stem-cell based therapies. There is therefore an urgent need to revisit the trials that have already been done with fetal VM tissue in PD patients, with the expectation that a critical reassessment can form the basis for an optimised and more standardised procedure that will translate into more consistently efficacious transplants with minimal side-effects. Over the last two years a group of international experts, including the key investigators of the previous European and North American trials, has been re-examining the outcome of these trials as well as reviewing the results obtained from recent and ongoing animal experimental studies, and identified a number of weaknesses that may explain the inconsistent outcome in previous trials. As a result of these discussions, the group has agreed to join forces in a new round of experimental work and cell therapy trials in PD, based on a new jointly developed protocol where all these factors are taken into account. In the first instance fetal VM tissue containing mesencephalic DA neuroblasts will be used, with the expectation that this will pave the way for bigger trials using dopaminergic neurons derived from stem cells.
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.2.1-2 | Award Amount: 8.14M | Year: 2014
Neuroimaging (NI) has enormous potential to improve the clinical care of patients with psychiatric disorders, but has yet to deliver. The PSYSCAN project will address this issue directly by developing a NI-based tool that will help clinicians resolve key clinical issues in the management of patients with psychotic disorders. Clinicians will use the tool to assess patients with a standardised set of NI and complementary demographic, clinical, cognitive, and genetic measures. The clinician will enter data on to an iPad, and these data, along with NI data will be electronically transferred to a central facility for analysis. Key features of the analysis include the assessment of NI data at a network level, the integration of NI and non-NI data, and the use of machine learning methods to make predictions specific to the patient being assessed. The results will be delivered to the clinicians iPad and will indicate the likelihood of a given clinical or functional outcome. The tool will have 3 clinical applications. PSYSCAN-Predict will facilitate prediction of the onset of psychosis in high risk subjects. PSYSCAN-Stratify will aid early diagnosis and the stratification of patients with first episode psychosis according to future course and outcome. PSYSCAN-Monitor will allow clinicians to measure progression of the disorder over time. Once developed, the tool will be validated in 2 large scale naturalistic studies using the consortiums extensive network of centres. The validated tool will then be disseminated to clinical centres across the EU. The PSYSCAN project involves a world-class consortium of experts on NI and psychiatry that unites academic centres, SMEs with image processing and computerised testing expertise, a large medical device provider, and the pharmaceutical industry. The consortium is thus ideally suited to translating expertise and knowledge in NI to build a tool that can be used to improve the care of patients with psychiatric disorders
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 2.10M | Year: 2013
Most of the 700,000 people in the UK with dementia have not received a formal diagnosis, so are denied access to benefitial treatments. The current NHS approach is slow (often more than 12 months) and often of low quality. This project will develop a novel digital healthcare system that will allow dementia diagnoses to be made quickly, cost effectively, and earlier in the diease course. It makes a novel combination of computer-based tests of memory and thinking and computerized analysis of MRI brain scans, which have been used in research for several years. It will provide support in diagnosis, making available the quality of information currently only available in highly specialist centres to doctors treating all patients, with the aim of reducing time to diagnosis to 3 months. We will build and test a prototype and demonstrate its value before developing a refined prototype that can be rolled-out nationally.
Husa A.P.,University of Oulu |
Rannikko I.,University of Oulu |
Moilanen J.,University of Oulu |
Haapea M.,University of Oulu |
And 8 more authors.
Schizophrenia Research | Year: 2014
Background: The association between the course of cognition and long-term antipsychotic medication in schizophrenia remains unclear. We analysed the association between cumulative lifetime antipsychotic medication dose and change of verbal learning and memory during a 9-year follow-up. Method: Forty schizophrenia subjects and 73 controls from the Northern Finland Birth Cohort 1966 were assessed by California Verbal Learning Test (CVLT) at the ages of 34 and 43 years. Data on the lifetime antipsychotic doses in chlorpromazine equivalents were collected. The association between antipsychotic dose-years and baseline performance and change in CVLT was analysed, controlling for baseline performance, gender, age of onset and severity of illness. Results: Higher antipsychotic dose-years by baseline were significantly associated with poorer baseline performance in several dimensions of verbal learning and memory, and with a larger decrease in short-delay free recall during the follow-up (p. =. 0.031). Higher antipsychotic dose-years during the follow-up were associated with a larger decrease of immediate free recall of trials 1-5 during the follow-up (p. =. 0.039). Compared to controls, decline was greater in some CVLT variables among those using high-doses, but not among those using low-doses. Conclusion: This is the first report of an association between cumulative lifetime antipsychotic use and change in cognition in a long-term naturalistic follow-up. The use of high doses of antipsychotics may be associated with a decrease in verbal learning and memory in schizophrenia years after illness onset. The results do not support the view that antipsychotics in general prevent cognitive decline or promote cognitive recovery in schizophrenia. © 2014 Elsevier B.V.
Barnett J.H.,University of Cambridge |
Barnett J.H.,Cambridge Cognition Ltd. |
Robbins T.W.,University of Cambridge |
Leeson V.C.,University College London |
And 4 more authors.
Neuroscience and Biobehavioral Reviews | Year: 2010
Cognitive dysfunction in schizophrenia is an important target for novel therapies. Effectively measuring the cognitive effects of compounds in clinical trials of schizophrenia could be a major barrier to drug development. The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) programme produced a consensus cognitive battery which is now widely used, however alternative assessments have advantages and disadvantages when compared with MATRICS. The Cambridge Neuropsychological Test Automated Battery (CANTAB) is a computerised assessment developed from animal behaviour paradigms and human neuropsychology. We review the utility of CANTAB according to MATRICS and CNTRICS recommendations. CANTAB tests have been used in more than 60 studies of psychotic disorders. Their neural bases are well understood through patient and neuroimaging studies and directly equivalent tests in rodents and non-human primates. The tests' sensitivity to pharmacological manipulation is well established. Future studies should collect more data regarding psychometric properties in patients over short time periods, and should continue to study the tests' relationships to functional outcomes. Computerised cognitive assessment may optimise the statistical power of cognitive trials by reducing measurement error and between-site variability and decreasing patient attrition through increased tolerability. © 2010 Elsevier Ltd.
Barnett J.H.,University of Cambridge |
Barnett J.H.,Cambridge Cognition Ltd |
Hachinski V.,London Health Sciences Center |
Blackwell A.D.,University of Cambridge |
Blackwell A.D.,Cambridge Cognition Ltd
BMC Medicine | Year: 2013
Background: Dementia is a major public health problem that poses an increasing burden on the health and wealth of societies worldwide. Because the efficacy of current treatments is limited, increasing efforts are required to prevent the diseases that cause dementia.Discussion: We consider the evidence that lifelong prevention strategies may be an effective way to tackle the national burden of dementia in the absence of a cure. The links between lifestyle and cardiovascular disease are widely understood and accepted, but health professionals and patients remain unconvinced about the extent to which risk for dementia can be modified. However, there is strong evidence that at least half of risk for dementia is attributable to lifestyle factors such as diet, exercise and smoking. Moreover, the disease processes that result in dementia develop over several decades, implying that attempts to ameliorate them need to start early in life. Some modifiable risk factors for dementia act from the earliest stages of life, including in utero.Summary: Rebalancing efforts from the development of treatments to increased emphasis on prevention may be an alternative means to reducing the impact of dementia on society. © 2013 Barnett et al.; licensee BioMed Central Ltd.
Khandaker G.M.,University of Cambridge |
Barnett J.H.,University of Cambridge |
Barnett J.H.,Cambridge Cognition Ltd. |
White I.R.,MRC Biostatistics Unit |
Jones P.B.,University of Cambridge
Schizophrenia Research | Year: 2011
Objective: A premorbid IQ deficit supports a developmental dimension to schizophrenia and its cognitive aspects that are crucial to functional outcome. Better characterisation of the association between premorbid IQ and the disorder may provide further insight into its origin and etiology. We aimed to quantify premorbid cognitive function in schizophrenia through systematic review and meta-analysis of longitudinal, population-based studies, and to characterize the risk of schizophrenia across the entire range of premorbid IQ. Method: Electronic and manual searches identified general population-based cohort or nested case-control studies that measured intelligence before onset of schizophrenic psychosis using standard psychometric tests, and that defined cases using contemporaneous ICD or DSM. Meta-analyses explored dose-response relationships between premorbid cognitive deficit (using full-scale, verbal and performance IQ) and risk of schizophrenia. Meta-regression analyses explored relationships with age of illness onset, change in premorbid intelligence over time and gender differences. Results: Meta-analysis of 4396 cases and over 745. 000 controls from 12 independent studies confirmed significant decrements in premorbid IQ (effect size -0.43) among future cases. Risk of schizophrenia operated as a consistent dose-response effect, increasing by 3.7% for every point decrease in IQ (p<0.0001). Verbal and nonverbal measures were equally affected. Greater premorbid IQ decrement was associated with earlier illness onset (p < 0.0001). There was no evidence of a progressively increasing deficit during the premorbid period toward illness onset. Conclusions: Strong associations between premorbid IQ and risk for schizophrenia, and age of illness onset argue for a widespread neurodevelopmental contribution to schizophrenia that operates across the entire range of intellectual ability. This also suggests higher IQ may be protective in schizophrenia, perhaps by increasing active cognitive reserve. © 2011 Elsevier B.V.
Cambridge Cognition Ltd | Date: 2014-05-20
Computer software for use in the field of cognitive testing for monitoring, diagnosis, research, analysis and assessment; computer software for use in clinical trials for use in monitoring, diagnosis, research, analysis and assessment of cognitive abilities; computer software for use in the field of psychological monitoring, diagnosis, research, analysis and assessment; computer software for use in the field of neuropsychological testing, monitoring, diagnosis, research, analysis and assessment; computer software for use in the field of psychiatric testing, monitoring, diagnosis, research, analysis and assessment; blank digital storage media for recording data magnetically, optically, electronically, or in other machine readable form; computer hardware; measuring and testing apparatus and instruments for use in the field of cognitive, psychological, neuropsychological, or psychiatric testing, monitoring, diagnosis, research, analysis, or assessment, namely, touchscreen computers with response characteristics needed to detect and measure the responses to stimuli or alternative computer peripheral device, namely, a two-button press pad with response characteristics needed to detect and measure the responses to stimuli; downloadable instructional and teaching apparatus and instruments for use in the field of cognitive, psychological, neuropsychological and psychiatric testing and assessment, namely, manuals describing the use of the software; downloadable publications, namely, books, articles, journals, leaflets in the field of cognitive, psychological, neuropsychological, or psychiatric testing, monitoring, diagnosis, research, analysis, or assessment; all for or relating to cognitive, psychological, neuropsychological, or psychiatric testing, monitoring, diagnosis, research, analysis, or assessment. Medical apparatus and instruments in the nature of medical electrodes, cardiac and heart rate monitors, digital sensors, biofeedback sensors, respiratory sensors, sensors to monitor physical movements of a person, sensors to gather biometric data, all for use in the testing, monitoring, diagnosis, analysis and assessment of psychological, neuropsychological, psychiatric and cognitive function; diagnostic apparatus for medical purposes, namely, apparatus used in diagnosing and assessing cognitive, psychological, neuropsychological and psychiatric disorders. Advisory services for or relating to cognitive, psychological, neuropsychological, or psychiatric testing, monitoring, diagnosis, analysis, or assessment; professional medical consultancy services and provision of medical information and preparation of medical reports, all for or relating to cognitive, psychological, neuropsychological, or psychiatric testing, monitoring, diagnosis, analysis, or assessment.
Cambridge Cognition Ltd | Date: 2012-04-13
Computer software for use in testing, monitoring, diagnosis, research, analysis and assessment of cognitive function in the fields of psychology, neuropsychology, psychiatry and cognition; Computer software for use in testing, monitoring, diagnosis, research, analysis and assessment of cognitive function for purposes of clinical trials; pre-recorded magnetic data carriers featuring software for use in testing, monitoring, diagnosis, research, analysis and assessment of cognitive function; electronic publications, namely, electronic books, electronic newsletters and journals, all relating to cognitive, psychological, neuropsychological and psychiatric testing and assessment; audio and video recordings, all in the fields of psychology, neuropsychology, psychiatry and cognition; optical communications systems comprised of sensors, buttons, touchscreens, video screens, cameras, microphones, speakers, computer processors, computer hard drives, computer memory and computer software for the transmission of data between two points; downloadable electronic data files featuring software for use in testing, monitoring, diagnosis, research, analysis and assessment of cognitive function; audio and video recordings, all in the fields of cognitive, psychological, neuropsychological and psychiatric testing and assessment; machine readable computer programs for use in cognitive testing and assessment, psychological testing and assessment, neuropsychological testing and assessment and psychiatric testing and assessment; computer hardware; Measuring and testing apparatus and instruments in the nature of computer software for use in testing human psychological, neuropsychological, psychiatric and cognitive function and also including instructional manuals sold as a unit. Medical apparatus and instruments in the nature of medical electrodes, cardiac and heart rate monitors, digital sensors, biofeedback sensors, respiratory sensors, sensors to monitor physical movements of a person, sensors to gather biometric data, all for use in the testing, monitoring, diagnosis, analysis and assessment of psychological, neuropsychological, psychiatric and cognitive function; diagnostic apparatus for medical purposes, namely, apparatus used in diagnosing and assessing cognitive, psychological, neuropsychological and psychiatric disorders. Advisory services in the fields of cognitive testing, monitoring, diagnosis, analysis and assessment; advisory services in the fields of psychological testing, monitoring, diagnosis, analysis and assessment; advisory services relating to neuropsychological testing, monitoring, diagnosis, analysis and assessment; advisory services relating to psychiatric testing, monitoring, diagnosis, analysis and assessment; professional consultancy services in the field of cognitive testing, monitoring, diagnosis, analysis and assessment, psychological testing, monitoring, diagnosis, analysis and assessment, neuropsychological testing, monitoring, diagnosis, analysis and assessment and psychiatric testing, monitoring, diagnosis, analysis and assessment; and provision of medical information in the fields of psychology, neuropsychology, psychiatry and cognition; provision of online medical information in the fields of psychology, neuropsychology, psychiatry and cognition; advisory and information services, namely, the preparation of medical diagnostic reports relating to neuropsychology, psychiatry, psychology, and cognitive function.